The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer

The rebel angel: mutant p53 as the driving oncogene in breast cancer

(2012) D. Walerych et al.   CARCINOGENESIS

Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus

(2012) Florine Kastelein et al.   GUT

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

(2012) Hyesil Seol et al.   MODERN PATHOLOGY

Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

(2011) David Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods

(2011) J. M. S. Bartlett et al.   JOURNAL OF CLINICAL PATHOLOGY

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

(2011) Hervé Bonnefoi et al.   LANCET ONCOLOGY

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

(2011) Anna Yemelyanova et al.   MODERN PATHOLOGY

Tumour evolution inferred by single-cell sequencing

(2011) Nicholas Navin et al.   NATURE

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

A comparison between p53 accumulation determined by immunohistochemistry andTP53mutations as prognostic variables in tumours from breast cancer patients

(2008) Jan Alsner et al.   ACTA ONCOLOGICA

HER2 testing in the UK: further update to recommendations

(2008) R A Walker et al.   JOURNAL OF CLINICAL PATHOLOGY